News

2 Minute Medicine22h
Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension
In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...
News-Medical.Net on MSN1d
New screening tool enhances early detection of pulmonary hypertension
A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...
Cambridge Network3d
Overcoming challenges in Pulmonary Hypertension
Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...
Medical Dialogues11d
FDA Approves Treprostinil Inhalation Powder to Expand Treatment for PAH and PH-ILD
The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in ...
The New England Journal of Medicine2mon
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
≥11) and pulmonary arterial hypertension subtype (associated with ... prespecified criteria that were based on hemoglobin levels and platelet counts, with dose modifications indicated for ...
New therapy shows dramatic survival benefits in advanced pulmonary arterial hypertension
A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease.